We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
News

Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim

Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
News

Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec. 

Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the twenty-first milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into pre-clinical development of which one is already in Phase I clinical trials. Our collaboration with Boehringer Ingelheim continues to support Evotec’s overall strategy of building up a pipeline of assets of which we have interest in future upside.”

Advertisement